Osteoporosis International

, Volume 23, Issue 5, pp 1645–1650

Osteoid osteoma is an osteocalcinoma affecting glucose metabolism

  • C. B. Confavreux
  • O. Borel
  • F. Lee
  • G. Vaz
  • M. Guyard
  • C. Fadat
  • M.-C. Carlier
  • R. Chapurlat
  • G. Karsenty
Case Report


Osteocalcin is a hormone secreted by osteoblasts, which regulates energy metabolism by increasing β-cell proliferation, insulin secretion, insulin sensitivity, and energy expenditure. This has been demonstrated in mice, but to date, the evidence implicating osteocalcin in the regulation of energy metabolism in humans are indirect. To address this question more directly, we asked whether a benign osteoblastic tumor, such as osteoma osteoid in young adults, may secrete osteocalcin. The study was designed to assess the effect of surgical resection of osteoid osteoma on osteocalcin and blood glucose levels in comparison with patients undergoing knee surgery and healthy volunteers. Blood collections were performed the day of surgery and the following morning after overnight fasting. Patients and controls were recruited in the orthopedic surgery department of New York Presbiterian Hospital, NY-USA and Hospices Civils de Lyon, France. Seven young males were included in the study: two had osteoid osteoma, two underwent knee surgery, and three were healthy volunteers. After resection of the osteoid osteomas, we observed a decrease of osteocalcin by 62% and 30% from the initial levels. Simultaneously, blood glucose increased respectively by 32% and 15%. Bone turnover markers were not affected. This case study shows for the first time that osteocalcin in humans affects blood glucose level. This study also suggests that ostoid osteoma may be considered, at least in part, as an osteocalcinoma.


Adenoma Blood glucose Endocrine tumor Osteocalcin Osteoid osteoma 


  1. 1.
    Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207PubMedCrossRefGoogle Scholar
  2. 2.
    Karsenty G (2006) Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 4:341–348PubMedCrossRefGoogle Scholar
  3. 3.
    Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469PubMedCrossRefGoogle Scholar
  4. 4.
    Confavreux CB (2011) Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney Int 79(Suppl 121):S14–S19CrossRefGoogle Scholar
  5. 5.
    Confavreux CB, Levine RL, Karsenty G (2009) A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 310:21–29PubMedCrossRefGoogle Scholar
  6. 6.
    Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270PubMedCrossRefGoogle Scholar
  7. 7.
    Heikkinen S, Argmann CA, Champy MF et al (2007) Evaluation of glucose homeostasis. Curr Protoc Mol Biol Chapter 29:Unit 29B 23Google Scholar
  8. 8.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMedCrossRefGoogle Scholar
  9. 9.
    Hinoi E, Gao N, Jung DY, Yadav V, Yoshizawa T, Myers MG Jr, Chua SC Jr, Kim JK, Kaestner KH, Karsenty G (2008) The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol 183:1235–1242PubMedCrossRefGoogle Scholar
  10. 10.
    Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109:1321–1326PubMedGoogle Scholar
  11. 11.
    Mork NL, Robertson RP (1983) Effects of nonsteroidal antiinflammatory drugs in conventional dosage on glucose homeostasis in patients with diabetes. West J Med 139:46–49PubMedGoogle Scholar
  12. 12.
    Fleischman A, Shoelson SE, Bernier R, Goldfine AB (2008) Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 31:289–294PubMedCrossRefGoogle Scholar
  13. 13.
    Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE (2010) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346–357PubMedGoogle Scholar
  14. 14.
    Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE (2008) Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci 1:36–43PubMedCrossRefGoogle Scholar
  15. 15.
    Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, Forbes J, de Courten B, Krakoff J (2009) The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 52:385–393PubMedCrossRefGoogle Scholar
  16. 16.
    Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296–308PubMedCrossRefGoogle Scholar
  17. 17.
    Iki M, Tamaki J, Fujita Y et al (2011) Serum undercarboxylated osteocalcin levels are inversely associated with glycemic status and insulin resistance in an elderly Japanese male population: Fujiwara-kyo Osteoporosis Risk in Men (FORMEN) Study. Osteoporos Int (in press)Google Scholar
  18. 18.
    Bae SJ, Choe JW, Chung YE et al (2010) The association between serum osteocalcin levels and metabolic syndrome in Koreans. Osteoporos Int (in press)Google Scholar
  19. 19.
    Garcia-Martin A, Cortes-Berdonces M, Luque-Fernandez I et al (2010) Osteocalcin as a marker of metabolic risk in healthy postmenopausal women. Menopause (in press)Google Scholar
  20. 20.
    Hwang YC, Jeong IK, Ahn KJ, Chung HY (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772PubMedCrossRefGoogle Scholar
  21. 21.
    Kanazawa I, Yamaguchi T, Tada Y, Yamauchi M, Yano S, Sugimoto T (2011) Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. Bone 48:720–725PubMedCrossRefGoogle Scholar
  22. 22.
    Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:45–49PubMedCrossRefGoogle Scholar
  23. 23.
    Kanazawa I, Yamaguchi T, Yamauchi M, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2011) Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. Osteoporos Int 22:187–194PubMedCrossRefGoogle Scholar
  24. 24.
    Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellstrom D (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24:785–791PubMedCrossRefGoogle Scholar
  25. 25.
    Pittas AG, Harris SS, Eliades M, Stark P, Dawson-Hughes B (2009) Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab 94:827–832PubMedCrossRefGoogle Scholar
  26. 26.
    Saleem U, Mosley TH Jr, Kullo IJ (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30:1474–1478PubMedCrossRefGoogle Scholar
  27. 27.
    Yeap BB, Chubb SA, Flicker L, McCaul KA, Ebeling PR, Beilby JP, Norman PE (2010) Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia, and triglyceride levels. Eur J Endocrinol 163:265–272PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2011

Authors and Affiliations

  • C. B. Confavreux
    • 1
    • 2
  • O. Borel
    • 2
  • F. Lee
    • 3
  • G. Vaz
    • 4
  • M. Guyard
    • 4
  • C. Fadat
    • 2
  • M.-C. Carlier
    • 5
  • R. Chapurlat
    • 2
  • G. Karsenty
    • 1
  1. 1.Department of Genetics and Development, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  2. 2.Department of Rheumatology, Hospices Civils de LyonINSERM UMR 1033, Université de LyonLyonFrance
  3. 3.Department of Orthopedic Surgery, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  4. 4.Department of Orthopedic Surgery, Hospices Civils de LyonUniversité de LyonLyonFrance
  5. 5.Hospices Civils de Lyon, Fédération de Biochimie, Groupement Hospitalier SudPierre BéniteFrance

Personalised recommendations